奇正藏药：2025年扣非净利润4.77亿元 同比增长12.03%

Core Viewpoint - Qizheng Tibetan Medicine reported a revenue of 2.416 billion yuan for the fiscal year 2025, marking a year-on-year growth of 3.34%, with a net profit attributable to shareholders of 646 million yuan, up 10.98% [1] Group 1: Financial Performance - The company achieved a total operating revenue of 2.416 billion yuan, reflecting a growth of 3.34% year-on-year [1] - The net profit attributable to shareholders reached 646 million yuan, representing a year-on-year increase of 10.98% [1] - The net profit after deducting non-recurring gains and losses was 477 million yuan, which is a 12.03% increase compared to the previous year [1] Group 2: Business Operations - Qizheng Tibetan Medicine specializes in the research, production, and sales of Tibetan medicine, including external pain relief medications and oral Tibetan traditional medicines [1] - The growth in net profit for 2025 is primarily attributed to the increase in total operating revenue [1] Group 3: Regulatory Approval - The company's wholly-owned subsidiary in Macau recently obtained a registration certificate for traditional Chinese medicine from the Macau government [1] - The approved product, a classic Tibetan medicine called "Cuitang Granules," is now registered as an over-the-counter (OTC) medicine, allowing it to be sold directly to consumers through local retail pharmacies [1] - The prescription for Cuitang Granules is based on a Tibetan formula documented in the 15th century by renowned Tibetan medicine scholar Suka Nyangni Dorgi, intended for respiratory ailments [1]